Cargando…
P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE)
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430751/ http://dx.doi.org/10.1097/01.HS9.0000972448.04902.65 |
| _version_ | 1785091041492205568 |
|---|---|
| author | Kris Michael, Mahadeo Robert, Baiocchi Amer, Beitinjaneh Sridhar, Chaganti Choquet, Sylvain Dierickx, Daan Rajani, Dinavahi Gamelin, Laurence Ghobadi, Armin Norma, Guzman-Becerra Manher, Joshi Aditi, Mehta Sarah, Nikiforow Ran, Reshef Wei, Ye Susan, Prockop |
| author_facet | Kris Michael, Mahadeo Robert, Baiocchi Amer, Beitinjaneh Sridhar, Chaganti Choquet, Sylvain Dierickx, Daan Rajani, Dinavahi Gamelin, Laurence Ghobadi, Armin Norma, Guzman-Becerra Manher, Joshi Aditi, Mehta Sarah, Nikiforow Ran, Reshef Wei, Ye Susan, Prockop |
| author_sort | Kris Michael, Mahadeo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430751 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104307512023-08-17 P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE) Kris Michael, Mahadeo Robert, Baiocchi Amer, Beitinjaneh Sridhar, Chaganti Choquet, Sylvain Dierickx, Daan Rajani, Dinavahi Gamelin, Laurence Ghobadi, Armin Norma, Guzman-Becerra Manher, Joshi Aditi, Mehta Sarah, Nikiforow Ran, Reshef Wei, Ye Susan, Prockop Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430751/ http://dx.doi.org/10.1097/01.HS9.0000972448.04902.65 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Kris Michael, Mahadeo Robert, Baiocchi Amer, Beitinjaneh Sridhar, Chaganti Choquet, Sylvain Dierickx, Daan Rajani, Dinavahi Gamelin, Laurence Ghobadi, Armin Norma, Guzman-Becerra Manher, Joshi Aditi, Mehta Sarah, Nikiforow Ran, Reshef Wei, Ye Susan, Prockop P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE) |
| title | P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE) |
| title_full | P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE) |
| title_fullStr | P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE) |
| title_full_unstemmed | P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE) |
| title_short | P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE) |
| title_sort | p1390: new and updated results from a multicenter open-label global phase3 study of tab-cel for ebv+ptld following hct or sot after failure of rituximab or rituximab+chemotherapy (allele) |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430751/ http://dx.doi.org/10.1097/01.HS9.0000972448.04902.65 |
| work_keys_str_mv | AT krismichaelmahadeo p1390newandupdatedresultsfromamulticenteropenlabelglobalphase3studyoftabcelforebvptldfollowinghctorsotafterfailureofrituximaborrituximabchemotherapyallele AT robertbaiocchi p1390newandupdatedresultsfromamulticenteropenlabelglobalphase3studyoftabcelforebvptldfollowinghctorsotafterfailureofrituximaborrituximabchemotherapyallele AT amerbeitinjaneh p1390newandupdatedresultsfromamulticenteropenlabelglobalphase3studyoftabcelforebvptldfollowinghctorsotafterfailureofrituximaborrituximabchemotherapyallele AT sridharchaganti p1390newandupdatedresultsfromamulticenteropenlabelglobalphase3studyoftabcelforebvptldfollowinghctorsotafterfailureofrituximaborrituximabchemotherapyallele AT choquetsylvain p1390newandupdatedresultsfromamulticenteropenlabelglobalphase3studyoftabcelforebvptldfollowinghctorsotafterfailureofrituximaborrituximabchemotherapyallele AT dierickxdaan p1390newandupdatedresultsfromamulticenteropenlabelglobalphase3studyoftabcelforebvptldfollowinghctorsotafterfailureofrituximaborrituximabchemotherapyallele AT rajanidinavahi p1390newandupdatedresultsfromamulticenteropenlabelglobalphase3studyoftabcelforebvptldfollowinghctorsotafterfailureofrituximaborrituximabchemotherapyallele AT gamelinlaurence p1390newandupdatedresultsfromamulticenteropenlabelglobalphase3studyoftabcelforebvptldfollowinghctorsotafterfailureofrituximaborrituximabchemotherapyallele AT ghobadiarmin p1390newandupdatedresultsfromamulticenteropenlabelglobalphase3studyoftabcelforebvptldfollowinghctorsotafterfailureofrituximaborrituximabchemotherapyallele AT normaguzmanbecerra p1390newandupdatedresultsfromamulticenteropenlabelglobalphase3studyoftabcelforebvptldfollowinghctorsotafterfailureofrituximaborrituximabchemotherapyallele AT manherjoshi p1390newandupdatedresultsfromamulticenteropenlabelglobalphase3studyoftabcelforebvptldfollowinghctorsotafterfailureofrituximaborrituximabchemotherapyallele AT aditimehta p1390newandupdatedresultsfromamulticenteropenlabelglobalphase3studyoftabcelforebvptldfollowinghctorsotafterfailureofrituximaborrituximabchemotherapyallele AT sarahnikiforow p1390newandupdatedresultsfromamulticenteropenlabelglobalphase3studyoftabcelforebvptldfollowinghctorsotafterfailureofrituximaborrituximabchemotherapyallele AT ranreshef p1390newandupdatedresultsfromamulticenteropenlabelglobalphase3studyoftabcelforebvptldfollowinghctorsotafterfailureofrituximaborrituximabchemotherapyallele AT weiye p1390newandupdatedresultsfromamulticenteropenlabelglobalphase3studyoftabcelforebvptldfollowinghctorsotafterfailureofrituximaborrituximabchemotherapyallele AT susanprockop p1390newandupdatedresultsfromamulticenteropenlabelglobalphase3studyoftabcelforebvptldfollowinghctorsotafterfailureofrituximaborrituximabchemotherapyallele |